Skip to search formSkip to main contentSkip to account menu

tecadenoson

Known as: N-(3-tetrahydrofuranyl)-6-aminopurine riboside 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

AdenosineFuransPurinergic P1 Receptor Agonists

Narrower (1)

CVT 510
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Electrophysiologic Disorders Termination of Paroxysmal Supraventricular Tachycardia by Tecadenoson ( CVT-510 ) , a Novel A 1-Adenosine Receptor Agonist
Termination of Paroxysmal Supraventricular Tachycardia by Tecadenoson (CVT-510), a Novel A1-Adenosine Receptor Agonist Eric N… 
2015
2015
Noninvasive Assessment of Atrioventricular Nodal Function: Effect of Rate‐Control Drugs during Atrial Fibrillation
During atrial fibrillation (AF), conventional electrophysiological techniques for assessment of refractory period or conduction… 
2013
2013
Modification of atrioventricular node conduction increases RR variability but not RR irregularity nor atrial fibrillation rate in atrial fibrillation patients
We aimed at studying whether variability and irregularity of RR are modified by the selective A1 adenosine receptor agonist… 
Review
2008
Review
2008
A1 adenosine receptor agonists and their potential therapeutic applications
Background: The challenges in developing any A1 adenosine receptor (A1-AdoR) agonist involve having the desired effect on target… 
2006
2006
2’-C-Methyl derivatives of tecadenoson and 2-chloro-tecadenoson with increased selectivity for human A1 adenosine receptor
2005
2005
Affinity and selectivity of tecadenoson, 2-chloro-tecadenoson and 2’-C-methyl analogues at bovine and pig A1 adenosine receptor
2004
2004
Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of…
2003
2003
Trial to Evaluate the Management of PSVT During Electrophysiologic Study with Tecadenoson (TEMPEST)
Introduction: Tecadenoson, a selective A1 adenosine derivative,prolongs AV nodal conduction without A2-mediated reductions in BP… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
Tecadenoson: Antiarrhythmic, adenosine A1 agonist
Adenosine has been shown to be a clinically effective antiarrhythmic agent. However, because it acts on all 4 adenosine cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)